On September 7, 2022 XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:00 AM ET (Press release, Xoma, SEP 7, 2022, View Source [SID1234619177]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available live at https://bit.ly/3PLRYrA or by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of the presentation will be available and archived on the XOMA website for 90 days following the event.

On September 7, 2022 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022 (Press release, Leap Therapeutics, SEP 7, 2022, View Sourcenews-releases/news-release-details/leap-therapeutics-participate-baird-2022-global-healthcare" target="_blank" title="View Sourcenews-releases/news-release-details/leap-therapeutics-participate-baird-2022-global-healthcare" rel="nofollow">View Source [SID1234619176]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On September 7, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022 (Press release, DiaMedica, SEP 7, 2022, View Source [SID1234619174]). Management will conduct one-on-one meetings with investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.

On September 7, 2022 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022 (Press release, Moleculin, SEP 7, 2022, https://moleculin.com/moleculin-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference/ [SID1234619172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand through the H.C. Wainwright conference platform beginning Monday, September 12 at 7:00 AM ET for 30-days to those registered for the event.

On September 7, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported that Stephen R. Brady, chief executive officer of Tempest, will present at the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Tempest Therapeutics, SEP 7, 2022, View Source [SID1234619171]). The company presentation will be available for on-demand viewing Monday, September 12, 2022, at 7:00 a.m. ET on the investor section of the Tempest website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!